Skip to main content
SpringerLink
Log in

Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

A Correction to this article was published on 18 October 2022

This article has been updated

Abstract

Giant cell tumor of bone (GCTB), is a rare intermediate malignant bone tumor with high local infiltrative ability, and is genetically characterized by mutation in the H3-3A gene. Standard treatment is curative surgical tumor resection. GCTB demonstrates both local recurrence and pulmonary metastasis after surgical treatment, and effective systematic chemotherapy is yet to be established. Therefore, development of novel chemotherapies for GCTB is necessary. Although patient-derived tumor cell lines are potent tools for preclinical research, 15 GCTB cell lines have been reported to date, and only four are publicly available. Thus, this study aimed to establish and characterize a novel GCTB cell line for preclinical studies on GCTB. Herein, we described the establishment of a cell line, NCC-GCTB5-C1, from the primary tumor tissue of a patient with GCTB. NCC-GCTB5-C1 was shown to harbor a mutation in the H3-3A gene, which is typical of GCTB; thus, it has useful properties for in vitro studies. We conducted the largest integrated screening analysis of 214 antitumor agents using NCC-GCTB5-C1 along with four GCTB cell lines. Romidepsin (a histone deacetylase inhibitor), camptothecin, and actinomycin D (topoisomerase inhibitors) demonstrated remarkable antitumor effects, suggesting that these antitumor agents are potential therapeutic candidates for GCTB treatment. Therefore, the NCC-GCTB5-C1 cell line could potentially contribute to the elucidation of GCTB pathogenesis and the development of novel GCTB treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

References

  1. van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19:550–61.

    Article  Google Scholar 

  2. López-Pousa A, Martín Broto J, Garrido T, Vázquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015;17:419–30.

    Article  Google Scholar 

  3. Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current concepts in the treatment of giant cell tumors of bone. Cancers (Basel). 2021;13:3647.

    Article  CAS  Google Scholar 

  4. Basu Mallick A, Chawla SP. Giant cell tumor of bone: an update. Curr Oncol Rep. 2021;23:51.

    Article  CAS  Google Scholar 

  5. Liede A, Bach BA, Stryker S, et al. Regional variation and challenges in estimating the incidence of giant cell tumor of bone. J Bone Jt Surg Am. 2014;96:1999–2007.

    Article  Google Scholar 

  6. Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39:1576–83.

    Article  Google Scholar 

  7. Presneau N, Baumhoer D, Behjati S, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113–23.

    Article  CAS  Google Scholar 

  8. Amary F, Berisha F, Ye H, et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41:1059–68.

    Article  Google Scholar 

  9. Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–82.

    Article  CAS  Google Scholar 

  10. Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics. 2013;33:197–211.

    Article  Google Scholar 

  11. Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev. 2010;36:1–7.

    Article  Google Scholar 

  12. Jamshidi K, Gharehdaghi M, Hajialiloo SS, Mirkazemi M, Ghaffarzadehgan K, Izanloo A. Denosumab in patients with giant cell tumor and its recurrence: a systematic review. Arch Bone Jt Surg. 2018;6:260–8.

    PubMed  PubMed Central  Google Scholar 

  13. Chan CM, Adler Z, Reith JD, Gibbs CP Jr. Risk factors for pulmonary metastases from giant cell tumor of bone. J Bone Jt Surg Am. 2015;97:420–8.

    Article  Google Scholar 

  14. Dominkus M, Ruggieri P, Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumours–14 cases from a single institution. Int Orthop. 2006;30:499–504.

    Article  CAS  Google Scholar 

  15. Wang J, Liu X, Yang Y, et al. Pulmonary metastasis of giant cell tumour: a retrospective study of three hundred and ten cases. Int Orthop. 2021;45:769–78.

    Article  Google Scholar 

  16. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3–13.

    Article  CAS  Google Scholar 

  17. Tseng YY, Boehm JS. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Curr Opin Genet Dev. 2019;54:33–40.

    Article  CAS  Google Scholar 

  18. Hattori E, Oyama R, Kondo T. Systematic review of the current status of human sarcoma cell lines. Cells. 2019;8:157.

    Article  CAS  Google Scholar 

  19. Hideyuki T, Yoko T, Daisuke M, Miharu K, Tohru M, Hiroshi M. Cell line individualization by STR multiplex system in the cell bank found cross-contamination between ECV304 and EJ-1/T24. Tissue Cult Res Commun. 1999;18:329–38.

    Google Scholar 

  20. Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A. 2001;98:8012–7.

    Article  CAS  Google Scholar 

  21. Drexler HG, Dirks WG, MacLeod RA, Uphoff CC. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal. Int J Cancer. 2017;140:1209–14.

    Article  CAS  Google Scholar 

  22. Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

    Article  CAS  Google Scholar 

  23. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope. 2001;111:696–701.

    Article  CAS  Google Scholar 

  24. Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Hum Cell. 2020;33:1321–8.

    Article  CAS  Google Scholar 

  25. Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2021;34:1899–910.

    Article  CAS  Google Scholar 

  26. Ono T, Noguchi R, Yoshimatsu Y, et al. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Hum Cell. 2022;35:392–9.

    Article  CAS  Google Scholar 

  27. Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.

    Article  Google Scholar 

  28. Skok Ž, Zidar N, Kikelj D, Ilaš J. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J Med Chem. 2020;63:884–904.

    Article  CAS  Google Scholar 

  29. Zarin DA, Fain KM, Dobbins HD, Tse T, Williams RJ. 10-year update on study results submitted to ClinicalTrials.gov. N Engl J Med. 2019;381:1966–74.

    Article  Google Scholar 

  30. Shinn P, Chen L, Ferrer M, et al. High-throughput screening for drug combinations. Methods Mol Biol. 2019;1939:11–35.

    Article  CAS  Google Scholar 

  31. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005;11:8467–75.

    Article  CAS  Google Scholar 

  32. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004;92:223–37.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs. E. Kobayashi, S. Iwata, K.Ogura, S.Osaki, K.Sato, C.Sato, S.Ishihara (Department of Musculoskeletal Oncology), and the National Cancer Center Hospital for sampling tumor tissue specimens from surgically resected materials. We also appreciate the technical assistance provided by Mrs. Y. Kuwata (Division of Rare Cancer Research) and technical support provided by Mrs. Y. Shiotani, Mr. N. Uchiya, and Dr. T. Imai (Central Animal Division, National Cancer Center Research Institute). We would like to thank Editage (www.editage.jp) for providing English language editing services and for their constructive comments on this manuscript. This study was technically assisted by the Fundamental Innovative Oncology Core of the National Cancer Center.

Funding

This research was supported by the Japan Agency for Medical Research and Development (Grant number: 20ck0106537h0002).

Author information

Author notes

  1. Yuki Yoshimatsu

    Present address: Division of Patient-Derived Cancer Model, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Taro Akiyama, Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Ryuto Tsuchiya, Takuya Ono & Tadashi Kondo

  2. The Department of Orthopaedic Surgery, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-0856, Japan

    Taro Akiyama, Ryuto Tsuchiya & Seji Ohtori

  3. Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Suguru Fukushima, Yu Toda & Akira Kawai

  4. Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Naoki Kojima & Akihiko Yoshida

Authors
  1. Taro Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuki Yoshimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yooksil Sin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuya Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Suguru Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu Toda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoki Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Seji Ohtori
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

The ethical committee of the National Cancer Center approved the use of clinical materials for this study (approval number: 2004-050). Animal experiments were conducted in compliance with the guidelines of the Institute for Laboratory Animal Research, National Cancer Center Research Institute.

Informed consent

Written informed consent was provided by the patient.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

13577_2022_724_MOESM1_ESM.tiff

Supplementary file1 Short tandem repeat patterns of NCC-GCTB5-C1 and the original tumor tissue (a) Short tandem repeat patterns of the original tumor tissue of NCC-GCTB5-C1 and (b) short tandem repeat patterns of NCC-GCTB5-C1 cells (passage 25) (TIFF 3925 KB)

Supplementary file2 (XLSX 12 KB)

Supplementary file3 (XLSX 22 KB)

Supplementary file4 (XLSX 52 KB)

Supplementary file5 (XLSX 15 KB)

Supplementary file6 (XLSX 15 KB)

Supplementary file7 (XLSX 13 KB)

Supplementary file8 (XLSX 13 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akiyama, T., Yoshimatsu, Y., Noguchi, R. et al. Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone. Human Cell 35, 1621–1629 (2022). https://doi.org/10.1007/s13577-022-00724-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-022-00724-2

Keywords

Search

Navigation